Abstracts tagged "Systemic JIA and interleukins (IL)"

Abstract Number: 2422 • 2015 ACR/ARHP Annual Meeting
Efficacy and Safety of Canakinumab in Children with Systemic Juvenile Idiopathic Arthritis: Results from the Phase 3 Extension Study
Hermine I. Brunner¹, Nicolino Ruperto², Pierre Quartier³, Tamas Constantin², Ekaterina Alexeeva², Isabelle Koné-Paut², Katherine Marzan¹, Nico Wulffraat², Rayfel Schneider¹, Shai Padeh², Vyacheslav Chasnyk², Carine Wouters², Jasmin B. Kuemmerle-Deschner², Tilmann Kallinich², Bernard Lauwerys⁴, Elie Haddad¹, Evgeny Nasonov², Maria Trachana², Olga Vougiouka², Karolynn Leon⁵, Antonio Speziale⁶, Karine Lheritier⁶, Alberto Martini², Daniel Lovell^1,7 and on behalf of PRINTO/PRCSG, ¹PRCSG, Cincinnati, OH, ²PRINTO-Istituto Gaslini, Genova, Italy, ³Necker-Enfants Malades Hospital, Paris, France, ⁴Cliniques Universitaires Saint-Luc and Université Catholique de Louvain, Brussels, Belgium, ⁵Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁶Novartis Pharma AG, Basel, Switzerland, ⁷Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH
Background/Purpose: Systemic juvenile idiopathic arthritis (SJIA) is a debilitating form of arthritis associated with systemic symptoms such as anemia, rash, leukocytosis, elevated erythrocyte sedimentation rate…
Abstract Number: 2291 • 2014 ACR/ARHP Annual Meeting
Canakinumab in Biologic-naïve Versus Previously Biologic-Exposed Systemic Juvenile Idiopathic Arthritis Patients: Efficacy Results from a 12 Week Pooled Post Hoc Analysis
A Grom¹, P Quartier², N Ruperto³, H.I Brunner¹, K Schikler¹, M Erguven³, L Goffin³, M Hofer³, T Kallinich³, K Marzan¹, C Gaillez⁴, K Lheritier⁴, K Abrams⁵, A Martini³ and D.J Lovell¹, ¹PRCSG, Cincinnati, OH, ²Hôpital Necker-Enfants Malades, Paris, France, ³PRINTO-Istituto Gaslini, Genova, Italy, ⁴Novartis Pharma AG, Basel, Switzerland, ⁵Novartis Pharmaceutical Corporation, East Hanover, NJ
Background/Purpose: Efficacy and safety of canakinumab (CAN), a selective, human, anti-IL-1β monoclonal antibody, was previously demonstrated in 2 phase III trials.1 Out of these trials…
Abstract Number: 309 • 2014 ACR/ARHP Annual Meeting
Clinical Significance of Cytokine Profile with Interleukin-18 and -6 in Systemic Juvenile Idiopathic Arthritis
Masaki Shimizu, Natsumi Inoue, Yuko Tasaki, Sayaka Ishikawa, Kazuyuki Ueno and Akihiro Yachie, Department of Pediatrics, School of Medicine, Institute of Medical, Pharmaceutical, and Health Sciences, Kanazawa University, Kanazawa, Japan
Background/Purpose Innate proinflammatory cytokines interleukin (IL)-6 and IL-18 are critical for perpetuating the inflammatory processes in systemic juvenile idiopathic arthritis (s-JIA) and macrophage activation syndrome…
Abstract Number: 1692 • 2013 ACR/ARHP Annual Meeting
Characterization Of Changes In Gene Expression and Inflammatory Proteins In Systemic Juvenile Idiopathic Arthritis Patients On Canakinumab Therapy
Nanguneri R. Nirmala¹, Nico Wulffraat², Hermine Brunner³, Pierre Quartier⁴, Riva Brik⁵, Liza McCann⁶, Huri Ozdogan⁶, Lidia Rutkowska-Sak⁶, Rayfel Schneider^3,7, Valeria Gerloni⁸, Liora Harel⁹, Maria Terreri³, Kristin Houghton³, Rik Joos⁶, Daniel Kingsbury³, Jorge M. Lopez-Benitez³, Arndt Brachat¹⁰, Stephan Bek¹⁰, Martin Schumacher¹⁰, Marie-Anne Valentin¹¹, Hermann Gram¹⁰, Ken Abrams¹², Alberto Martini⁶, Nicolino Ruperto⁶ and Daniel J. Lovell³, ¹Novartis Institutes for Biomedical Research, Cambridge, MA, ²PRINTO, Genoa, Italy, ³Pediatric Rheumatology Collaborative Study Group (PRCSG), Cincinnati, OH, ⁴Necker-Enfants Malades Hospital, Paris, France, ⁵Pediatrics, Rambam Medical Center, Haifa, Israel, ⁶Paediatric Rheumatology International Trials Organization (PRINTO), Genova, Italy, ⁷Pediatric Rheumatology Collaborative Study Group (PRCSG), Cincinnati, OH, Canada, ⁸Istituto Gaetano Pini, Milan, Italy, ⁹Pediatric Rheumatology unit, Schneider Children's Medical Center, Tel Aviv University, Petach Tikvah, Israel, ¹⁰Novartis Institutes for Biomedical Research, Basel, Switzerland, ¹¹Biomarker Development, Novartis Pharma AG, Basel, Switzerland, ¹²Novartis Pharmaceuticals Corporation, East Hanover, NJ
Background/Purpose: Interleukin (IL)-1β plays a key role in the pathogenesis of systemic juvenile idiopathic arthritis (SJIA). Canakinumab (CAN), a selective, fully human, anti-IL-1β monoclonal antibody,…
Abstract Number: 270 • 2013 ACR/ARHP Annual Meeting
Canakinumab In The Treatment Of Systemic Juvenile Idiopathic Arthritis: Results From a 12-Week Pooled Post-Hoc Analysis For Efficacy
Hermine Brunner¹, Pierre Quartier², Tamas Constantin³, Shai Padeh⁴, Inmaculada Calvo³, Muferet Erguven³, Laurence Goffin³, Michael Hofer⁵, Tilmann Kallinich³, Sheila Oliveira³, Yosef Uziel⁶, Stefania Viola⁷, Kiran Nistala³, Carine Wouters⁸, Karine Lheritier⁹, Josef Hruska⁹, Ken Abrams¹⁰, Alberto Martini³, Nicolino Ruperto³ and Daniel J. Lovell¹, ¹Pediatric Rheumatology Collaborative Study Group (PRCSG), Cincinnati, OH, ²Necker-Enfants Malades Hospital, Paris, France, ³Paediatric Rheumatology International Trials Organization (PRINTO), Genova, Italy, ⁴Sheba Medical Center, Tel-Hashomer, Israel, ⁵Centre Multisite Romand de Rhumatologie Pediatrique, Lausanne, Switzerland, ⁶Pediatric Rheumatology Unit , Department of Pediatrics, Meir Medical Center, Kfar Saba, Israel, ⁷Istituto G. Gaslini, Istituto Giannina Gaslini, Genova, Italy, ⁸PRINTO, Genoa, Italy, ⁹Novartis Pharma AG, Basel, Switzerland, ¹⁰Novartis Pharmaceuticals Corporation, East Hanover, NJ
Background/Purpose: Interleukin-1β (IL-1β) plays a key role in the pathogenesis of systemic juvenile idiopathic arthritis (SJIA), a severe disabling subtype of JIA characterized by arthritis…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].